title: Consequences of cardiovascular adaptation to spaceflight: implications for the use of pharmacological countermeasures.
abstract: There is little evidence obtained from space flight to support the notion that occurrence of cardiac dysrhythmias, impaired cardiac and vascular function, and manifestation of asymptomatic cardiovascular disease represent serious risks during space flight. Therefore, the development of orthostatic hypotension and instability immediately after return from spaceflight probably reflect the most significant operational risks associated with the cardiovascular system of astronauts. Significant reductions in stroke volume and lower reserve for increasing peripheral vascular resistance contribute to ineffective maintenance of systemic arterial blood pressure during standing after spaceflight despite compensatory elevations in heart rate. The primary mechanism underlying reduced stroke volume appears to be a reduction in preload associated with less circulating blood volume while inadequate peripheral vasoconstriction may be caused partly by hyporeactivity of receptors that control arterial smooth muscle function. A focus for development of future countermeasures for hemodynamic responses to central hypovolemia includes the potential application of pharmacological agents that specifically target and restore blood volume (e.g., fludrocortisone, electrolyte-containing beverages) and reserve for vasoconstriction (e.g., midodrine, vasopressin). Based on systematic evaluations, acute physical exercise designed to elicit maximal effort or inspiratory resistance have shown promise as successful countermeasures that provide protection against development of orthostatic hypotension and intolerance without potential risks and side effects associated with specific pharmacological interventions.
authors.affiliation: U.S. Army Institute of Surgical Research, Fort Sam Houston, Texas 78234-6513, USA. victor.convertino@amedd.army.mil
authors.forename: Victor A
authors.initials: VA
authors.lastname: Convertino
mesh_terms: D000222:Adaptation, Physiological; D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use; D000337:Aerospace Medicine; D018480:Astronauts; D001794:Blood Pressure / Q000502:physiology; D001810:Blood Volume / Q000502:physiology; D002302:Cardiac Output / Q000502:physiology; D018493:Cardiovascular Deconditioning / Q000187:drug effects / Q000502:physiology; D015444:Exercise / Q000502:physiology; D005438:Fludrocortisone / Q000627:therapeutic use; D006439:Hemodynamics / Q000502:physiology*; D006801:Humans; D007024:Hypotension, Orthostatic / Q000188:drug therapy* / Q000209:etiology; D008879:Midodrine / Q000627:therapeutic use; D012965:Sodium Chloride / Q000627:therapeutic use; D013026:Space Flight; D013318:Stroke Volume / Q000502:physiology; D014655:Vascular Resistance / Q000502:physiology; D014893:Weightlessness / Q000009:adverse effects*; D018544:Weightlessness Countermeasures
chemical_list: D000316:Adrenergic alpha-Agonists; D012965:Sodium Chloride; D008879:Midodrine; D005438:Fludrocortisone